[Chinese expert consensus on lipid management in patients with malignancy].

Patients with malignant tumors are often combined with dyslipidemia, and dyslipidemia is associated with both malignant tumor disease and treatment. The expert group of the Integrative Cardio-Oncology Society of China Anti-Cancer Association summarized the incidence rate and characteristics of dyslipidemia in patients with malignant tumors, and the characteristics and mechanisms of dyslipidemia induced by common antineoplastic drugs, stratified the risk of dyslipidemia in antineoplastic drugs, then formulated the principles of dyslipidemia treatment and monitoring. This consensus refers to domestic and aboard research progress, combineds with China's clinical experience to formulate the corresponding prevention and treatment of dyslipidemia. The present consensus provides practical strategies for clinicians in the management of dyslipidemia in malignant tumors and promotes the management of dyslipidemia in malignant tumors in China.恶性肿瘤患者常合并血脂异常，血脂异常既与恶性肿瘤疾病有关，又与疾病治疗有关。中国抗癌协会整合肿瘤心脏病学分会专家组总结了恶性肿瘤患者血脂异常的发生率和特征，汇总了常见抗肿瘤药物血脂异常的特点和发生机制，对抗肿瘤药物进行血脂异常危险分层，并制定血脂异常治疗及监测原则。专家参考国内外研究进展，结合中国临床经验制定了相应的血脂异常防治指引，旨在为临床医师提供切实可行的恶性肿瘤血脂管理策略，推进中国恶性肿瘤血脂异常的管理。.